Sono-Tek Corporation — FY2016 Form 10-K
Reporting period: Fiscal year ended February 29, 2016, compared with the year ended February 28, 2015. Although the request metadata says “2015 Q4,” this is an annual FY2016 filing, not a quarterly report.
Business context
Sono-Tek develops, manufactures, sells, installs, and services ultrasonic spray-coating systems and nozzles. Its applications span electronics, advanced energy, medical devices, glass, textiles, and food. The company also operates a real-estate segment. Its principal coating technology is marketed as reducing liquid use, overspray, and coating costs versus conventional spraying methods.
Financial results and liquidity
| Metric | FY2016 | FY2015 |
|---|---|---|
| Consolidated net sales | $11.834 million | $10.849 million |
| Gross profit | $5.638 million | $5.215 million |
| Gross margin | 47.6% | 48.1% |
| Operating income | $740,000 | $850,000 |
| Net income | $548,000 | $606,000 |
| Basic and diluted EPS | $0.04 | $0.04 |
| Cash provided by operations | $629,000 | $924,000 |
| Cash and cash equivalents | $2.388 million | $2.563 million |
| Marketable securities | $1.696 million | $1.652 million |
| Working capital | $5.855 million | $5.512 million |
| Total debt | $1.320 million | $1.478 million |
Operating cash flow less purchases of equipment, furnishings, and leasehold improvements was approximately $163,000. The company reported a 4.5-to-1 current ratio and no borrowings on its $750,000 revolving credit line. The outstanding mortgage note carries 4.15% interest and is secured by the company’s land and buildings. Net income margin was approximately 4.6%, versus 5.6% in FY2015. An unrealized $70,000 loss on available-for-sale securities reduced comprehensive income to $478,000; management said it did not consider the decline other-than-temporary.
Material changes versus FY2015
- Consolidated sales rose about 9%. Management attributed growth in ultrasonic-system sales mainly to WideTrack units, fluxers and related spares, servo units, and spray dryers; stent coaters, XYZ units, and nozzles and generators declined.
- Foreign sales increased 31% to $6.577 million and represented 56% of revenue, compared with 47% a year earlier. Western Europe and the Far East drove most of the increase.
- Gross profit increased, but gross margin edged down as sales mix shifted away from higher-margin stent coaters, XYZ units, and nozzles and generators.
- Research and product development expense rose 25% to $1.268 million; marketing and selling expense rose 10% to $2.371 million; general and administrative expense rose 6% to $1.100 million. Together, these increases exceeded gross-profit growth, contributing to lower operating and net income.
- Operating cash flow fell to $629,000 from $924,000, with lower customer deposits and payments of accounts payable, accrued expenses, and taxes among the cash-flow movements. The cash balance declined $174,000.
Outlook, commentary, risks, and unusual items
No quantified revenue, earnings, or margin guidance is provided. Management described product additions, expanded markets, and international reach as a foundation for future sales growth and improved profitability. It reported completion of two new products, VersiCoat and SonoBraze, and three patents granted during the year. Research and development spending increased to support product development.
The filing identifies risks including economic and business conditions; political, regulatory, competitive, and technological changes; timely development and acceptance of new products; financing adequacy; capacity additions; patent enforcement; and the ability to increase sales and sustain profitability. Foreign markets are significant: exports were 56% of sales. One customer represented 7% of annual sales, while four customers accounted for 40% of year-end receivables. The company had $72,446 of cash pledged to support bank guarantees for international customers. It reported no material commitments or contingencies, no legal proceedings, and no off-balance-sheet arrangements.
Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor issued an unqualified opinion on the financial statements. The company is a smaller reporting company and did not provide the risk-factor section required of larger filers.
Important facts for investors to verify
- Revenue basis: The MD&A cites $11.739 million of ultrasonic-spraying sales, while consolidated financial statements report $11.834 million of net sales. The segment table reconciles the difference through real-estate revenue and intercompany eliminations; confirm which figure is appropriate for any growth comparison.
- Operating-income presentation: MD&A reports ultrasonic-spraying operating income of $804,000, while the consolidated statement reports operating income of $740,291. Review segment and consolidated presentations before using either figure.
- Growth quality: Assess how sustainable export-led growth is and whether weaker sales in higher-margin product categories affect margins and earnings.
- Cash generation and liquidity: Monitor operating cash flow, customer deposits, working-capital movements, capital spending, and the company’s cash and marketable securities relative to mortgage repayments.
- Marketable-securities loss: Confirm subsequent valuation and whether the reported unrealized loss remained temporary.
- Customer and international exposure: Track customer receivable concentration, export demand, and the bank guarantees securing customer deposits.